Related Articles
Bevacizumab as a last-line treatment for glioblastoma following failure of radiotherapy, temozolomide and lomustine
Multimodal treatment for local recurrent malignant gliomas: Resurgery and/or reirradiation followed by chemotherapy
Outcome of patients with glioblastoma in Saudi Arabia: Single center experience
Bevacizumab treatment for newly diagnosed glioblastoma: Systematic review and meta-analysis of clinical trials
Effectiveness of the bevacizumab‑irinotecan regimen in the treatment of recurrent glioblastoma multiforme: Comparison with other second‑line treatments without this regimen